Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Attention-Deficit/Hyperactivity Disorder (ADHD)
Clinical Trial
NCT01107496Last updated: 12/4/2025
SUPN
SUPERNUS PHARMACEUTICALS, INC.